Nanotechnology Approaches for Prevention and Treatment of Chemotherapy‐Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors

Abstract

Nanotechnology has emerged as a promising approach for the targeted delivery of therapeutic agents while improving their efficacy and safety. As a result, nanomaterial development for the selective targeting of cancers, with the possibility of treating off‐target, detrimental sequelae caused by chemotherapy, is an important area of research. Breast and ovarian cancer are among the most common cancer types in women, and chemotherapy is an essential treatment modality for these diseases. However, chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy are common side effects that can affect breast and ovarian cancer survivors quality of life. Therefore, there is an urgent need to develop effective prevention and treatment strategies for these adverse effects. Nanoparticles (NPs) have extreme potential for enhancing therapeutic efficacy but require continued research to elucidate beneficial interventions for women cancer survivors. In short, nanotechnology‐based approaches have emerged as promising strategies for preventing and treating chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy. NP‐based drug delivery systems and therapeutics have shown potential for reducing the side effects of chemotherapeutics while improving drug efficacy. In this article, the latest nanotechnology approaches and their potential for the prevention and treatment of chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors are discussed.

Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly

“…Meanwhile, the presence and remission of ascites in this patient were closely related to the treatment, thus indicating that ascites may be an adverse effect of the anti-tumor therapy. Adverse reactions of chemotherapy mainly include adverse reactions at the injection site (phlebitis), digestive system adverse reactions (nausea and vomiting), bone marrow suppression, organ function damage (toxicity of heart, liver, and kidney), neurotoxicity, hair loss, and skin reactions while the adverse effects of monoclonal antibodytargeted therapy are hypersensitive reaction, arterial and venous thromboembolic events, diarrhea, nausea, vomiting, and so on (16)(17)(18). As for anti-Claudin18.2 antibody therapy, the most common adverse effects are vomiting and nausea (19).…”

Hyaluronic Acid-Mediated Phenolic Compound Nanodelivery for Cancer Therapy

“…Particularly, immunotherapy represents a change in paradigm in cancer therapy since, in this case, the antineoplastic agents, instead of directly contrasting cancer cells, have the potential to activate the patient’s immune system to become able to attack cancer cells powerfully and successfully. However, it should be underlined that the drawbacks existing for the conventional therapeutic approaches, such as low response rate, dangerous side effects, development of resistance, immunosuppression, and high recurrence rate chemotherapy, are also reported for the most innovative therapeutic strategies, and new routes are being investigated to overcome these problems [ 6 , 7 , 8 ].…”

Enzyme-Induced Shape-Shifting Peptide Nanocarrier Coloaded with Paclitaxel and Dipyridamole Inhibits Platelet Function and Tumor Metastasis

“…Chemotherapy is the main modality for tumor treatment . However, conventional chemotherapeutic drugs have problems, such as unsatisfactory effects and insufficient accumulation. − In recent years, nanocarriers have received increasing attention due to their excellent properties as drug delivery systems. , With the deepening of research, studies have shown that the nanoparticle size is closely linked to its penetration and accumulation abilities. Small nanoparticles easily penetrate deep into tumor tissues, but they can also be readily cleared, resulting in insufficient accumulation.…”